IPCA LABORATORIES PROSPERITY LIES IN GOOD HEALTH

Globally, India is known to be the largest provider of generic drugs. The Indian pharmaceutical sector supplies over 50 per cent of global demand for various vaccines with 40 per cent of generic demand in the US and 25 per cent of all the medicine in the UK. At such a juncture, Ipca Laboratories is well-poised to derive maximum mileage with its impressive product portfolio and research and development expertise

- 

Ipca Laboratories is a consumer-led pharmaceutical company, creating healthy doses of life since 1949. It has been a crucial healthcare partner across 120 countries and six continents. It is a fully integrated pharmaceutical company which manufactures over 350 formulations and 80 APIs for various therapeutic segments. The company stands out as one of the world’s largest manufacturers and suppliers of over a dozen APIs out of which it has manufacturing leadership in over 12 APIs globally. The API formulation division has been in the lead for 30 years and Ipca Laboratories produces over 80 APIs at 12 production facilities, accounting for nearly 25 percent of its turnover.

The core strategic focus has been on backward integration, resulting in superior supply chain reliability and cost competitiveness in a dynamic market. Ipca Laboratories has also emerged as one of India’s top exporters of APIs, serving over 70 countries around the globe. The APIs are produced from scratch at fully automated manufacturing facilities which are approved by well-known drug regulatory authorities like UK-MHRA, EDQM-Europe and WHO-Geneva, among others. The company has leading brands in pain, rheumatology, anti-malarial and hair care therapy in India. Also, four of its formulations rank amongst the top 300 brands of the Indian pharmaceutical market as per IQVIA, May 2020.